Cloudy or Particles in a Compounded GLP-1 Vial: Visual Inspection Guide
If your compounded semaglutide or tirzepatide looks cloudy, has floating specks, or has changed color since you got it, don't inject it. Set the vial aside, photograph it, and call the dispensing pharmacy. Brand-name GLP-1 labels say not to use the solution if you see particles or discoloration, and that same caution is the safest default for a compounded product that FDA has not reviewed.
Key takeaways
- Ozempic and Wegovy labels describe a solution that is clear and colorless. Zepbound's label allows clear and colorless to slightly yellow.
- All three labels say not to use the product if you see particles or discoloration.
- A compounded product's normal appearance depends on its formula. Ask your pharmacy what yours should look like, in writing, before you need it.
- Quarantine a suspect vial instead of throwing it away. The pharmacy, your prescriber, and FDA may need the lot number and the vial itself.
- Report problems to the pharmacy and to FDA MedWatch.
What the brand labels say a normal solution looks like
Brand prescribing information is the most authoritative public description of what these drugs should look like. It isn't written for compounded products, but it shows the standard manufacturers are held to.
| Product (brand) | Expected appearance | Label instruction |
|---|---|---|
| Ozempic (semaglutide) | Clear and colorless | "Do not use OZEMPIC® if particulate matter and coloration is seen" |
| Wegovy injection (semaglutide) | Clear, colorless, no particles | "Only use if the solution is clear, colorless, and contains no particles" |
| Zepbound (tirzepatide) | Clear and colorless to slightly yellow | "Do not use ZEPBOUND if particulate matter or discoloration is seen" |
Source: Ozempic prescribing information (rev. 05/2026); Wegovy prescribing information (rev. 06/2026); Zepbound prescribing information (rev. 08/2026).
Notice the difference for tirzepatide. A faint yellow tint is within the brand label's description, while semaglutide labels say colorless. That's why "is mine the right color?" has no universal answer for compounded products. The answer depends on the formula your pharmacy uses.
Why a compounded vial might legitimately look different
Some compounded GLP-1s contain added ingredients. Cyanocobalamin (vitamin B12), for example, is described in its own prescribing information as "dark red crystals or as an amorphous or crystalline red powder" (American Regent cyanocobalamin label). A product that includes it would not be expected to look colorless. If your product has any added ingredient, ask the pharmacy what color it should be. Don't guess, and don't compare it to a friend's vial from a different pharmacy.
How to inspect a vial: a five-step check
Manufacturers inspect injectables under controlled conditions. The USP standard for visible particulates, chapter <790>, uses light of 2,000 to 3,750 lux, black and white backgrounds, swirling or inverting the container, and about five seconds of viewing against each background (Shabushnig, "Visual Inspection of Injectable Products," presentation posted by FDA, 2022). You can borrow the idea at home, even without a light meter.
- Use good light. A bright window or a lamp works. Avoid dim rooms.
- Swirl gently. Turn or tilt the vial slowly. Vigorous shaking adds bubbles that can be mistaken for particles.
- Look against white. Hold the vial in front of a sheet of white paper for several seconds. Dark specks show up best here.
- Look against black. Repeat against a dark surface. Light-colored flecks, fibers, and haze show up best here.
- Compare to your reference. Check the result against the label description or the pharmacy's written description of your product.
Compare current GLP-1 options
If you're reconsidering your source, review care options and verify each pharmacy's license yourself.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Decision table: what you see and what to do
| What you see | Possible explanations | Suggested action |
|---|---|---|
| Clear, matches the pharmacy's description | Expected | Use as directed by your prescriber |
| Cloudy or hazy throughout | Contamination, precipitation, temperature damage | Do not use; quarantine; call pharmacy |
| Floating specks, fibers, or flakes | Foreign particles, stopper fragments, product degradation | Do not use; photograph; call pharmacy |
| Color change since the vial arrived | Degradation, contamination, temperature exposure | Do not use; call pharmacy |
| Ice crystals, or the vial was frozen | Freezing | Do not use; brand labels say not to use if frozen |
| Tiny round bubbles that rise | Air from handling | Let it settle and reinspect |
| Powder that won't fully dissolve after mixing | Reconstitution problem or product issue | Do not use; call pharmacy before trying again |
Sources: Ozempic, Wegovy, and Zepbound prescribing information; USP <790> inspection method. "Possible explanations" are general categories, not a diagnosis of any specific vial.
On freezing: the Ozempic label says, "Do not freeze OZEMPIC® and do not use OZEMPIC® if it has been frozen" (Ozempic PI). Peptide solutions are sensitive to temperature. If a compounded vial froze in transit or in the back of a refrigerator, ask the pharmacy before using it rather than relying on how it looks after it thaws.
Lyophilized (powder) products
Some compounded GLP-1s ship as a freeze-dried powder that you or the pharmacy mixes with a diluent. After mixing, the solution should match whatever the pharmacy's instructions say, which is usually fully dissolved with no visible clumps or film. If the powder cake doesn't dissolve, leaves residue, or the mixed solution is cloudy, stop and call the pharmacy. Ask for written reconstitution instructions in advance, including which diluent, how much, and how to mix it.
Diluents have their own inspection rules. The label for one bacteriostatic water product says drug products should be inspected for "particulate matter and discoloration" before use, where the solution and container permit (Hospira bacteriostatic water label).
Why this matters: a real FDA example
On November 1, 2024, FDA warned patients and health care professionals not to use compounded drugs from Fullerton Wellness in California, including semaglutide and tirzepatide. FDA said it received a complaint on August 14, 2024 about "a black particulate in a vial of semaglutide," and that during an October 2024 visit it observed that the company "used non-sterile ingredients to make these injectable drugs." FDA told patients who received the products to "stop using them and contact their health care professional" (FDA alert).
That case started with a patient noticing something in a vial. Visible particles are not always a sign of a sterility problem, but they can be, and a patient cannot tell the difference by looking.
What to document before you call
- Clear photos of the vial against white and dark backgrounds, plus the label.
- The pharmacy name, prescription number, lot number, and beyond-use date from the label.
- When it arrived, how it was packed, and whether the cold pack was still cold.
- How you stored it, and whether it has been punctured and how many times.
- Any symptoms if you already injected from it.
Keep the vial in its labeled box, separate from your other medication, and stored as directed. Don't discard it until the pharmacy tells you whether it needs it back.
How to report it
Start with the dispensing pharmacy, and tell your prescriber. You can also report a product quality problem or a side effect to FDA through MedWatch online at the FDA MedWatch reporting form. FDA notes that adverse events with compounded GLP-1s are likely underreported, because state-licensed pharmacies that aren't outsourcing facilities are not required to report to FDA. As of May 31, 2026, FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide (FDA).
Worked example
Suppose a reader's refill of compounded tirzepatide arrives, and on the third week she notices a faint haze she didn't see before. She checks it against white and black paper and the haze is still there. She stops, photographs the vial, writes down the lot number, and calls the pharmacy. The pharmacy asks her to return the vial and sends a replacement. She also files a MedWatch report and tells her prescriber she skipped that week's dose. This example is illustrative and does not describe any real person or pharmacy.
Questions to ask your pharmacy
- What should my product look like, including its exact color, and can you put that in writing?
- Does it contain any added ingredients, and do they affect appearance?
- What is your policy if a vial looks abnormal? Will you replace it, and do you want it returned?
- Has this lot had any other complaints or a recall?
- For powder products, what are the exact reconstitution steps and the expected appearance after mixing?
Where this guide stops
Looking at a vial cannot confirm that a product is sterile, correctly dosed, or free of invisible contaminants. A clear vial is not proof of quality. This guide does not diagnose any reaction or replace your pharmacist or prescriber. If you have symptoms after an injection, such as fever, spreading redness, or signs of an allergic reaction, contact your prescriber or seek care.
Compare available care options
If a quality problem has you weighing a different pharmacy or an FDA-approved product, verify the prescriber's and pharmacy's credentials and terms yourself. A listing is not a recommendation or a prescription.
Compare participating providers
Review current care options, then confirm licenses and quality policies directly with the pharmacy.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Disclosure: we may earn a commission if you use a listed provider. Compensation does not establish a provider's safety, legitimacy, or value.
Frequently asked questions
Should compounded semaglutide be cloudy?
Brand semaglutide labels describe a clear, colorless solution and say not to use it if you see particles or discoloration. If a compounded vial looks cloudy, don't inject it; set it aside and call the dispensing pharmacy.
Is a slightly yellow tirzepatide vial normal?
Zepbound's label describes its solution as clear and colorless to slightly yellow. A compounded product's expected color depends on its formula, so ask your pharmacy what your specific product should look like.
What should I do with a vial that has particles in it?
Don't use it. Photograph it against white and dark backgrounds, record the lot number and beyond-use date, keep it separate in its labeled box, and contact the pharmacy and your prescriber. You can also report it to FDA MedWatch.
Can I use a compounded GLP-1 vial that froze?
Brand labels such as Ozempic's say not to use the product if it has been frozen. Ask the dispensing pharmacy before using a compounded vial that froze, rather than relying on how it looks after thawing.
Sources
- FDA: Compounding Laws and Policies
- Ozempic prescribing information, Novo Nordisk (rev. 05/2026)
- Wegovy prescribing information, Novo Nordisk (rev. 06/2026)
- Zepbound prescribing information, Eli Lilly (rev. 08/2026)
- Cyanocobalamin injection prescribing information, American Regent
- Shabushnig JG. Visual Inspection of Injectable Products: More than Sorting Good from Bad (presentation posted by FDA, September 2022)
- Bacteriostatic Water for Injection, USP (Hospira) label
- FDA: Warning not to use compounded drugs from Fullerton Wellness (Nov. 1, 2024)
- FDA MedWatch online reporting form
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss (current as of Oct. 1, 2026)
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.